Also trades as: KTTA (NASDAQ) · $vol 0M
KTTAW NASDAQ
Pasithea Therapeutics Corp.
1W: +22.9%
1M: -31.2%
3M: -48.3%
YTD: -48.3%
1Y: -40.5%
$0.00
-0.00 (-38.67%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.1M
52W Range0.0075-0.0122
Volume250
Avg Volume26,378
Beta1.38
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOTiago Reis Marques
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2021-09-15
Websitepasitheaclinics.com
1111 Lincoln Road
Miami Beach, FL 33139
US
Miami Beach, FL 33139
US
702-514-4174
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.
Latest News
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Equities Analysts Offer Predictions for KTTA FY2026 Earnings
Analysts Offer Predictions for KTTA Q1 Earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Krishnan Kartik | 0 | — | 2026-05-01 | |
| STEINMAN LAWRENCE | A-Award | 152,783 | $0.84 | 2026-05-01 |
| Dumesnil Simon | A-Award | 152,783 | $0.84 | 2026-05-01 |
| Leahy Emer | A-Award | 152,783 | $0.84 | 2026-05-01 |
| Novak Alfred J | A-Award | 152,783 | $0.84 | 2026-05-01 |